The Effects of Allicor on Patients After Coronary Arteria Revascularization Treatment (TEA-CART)

Institute for Atherosclerosis Research, Russia

Status and phase: Enrolling; Phase 4

Conditions: Myocardial Ischemia; Percutaneous Coronary Revascularization; Coronary Arteriosclerosis; Coronary Artery Bypass Grafting

Treatments: Dietary Supplement: Allicor; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT05803759

IAR-AL-CAR

Details and patient eligibility

About

Coronary revascularization interventions such as coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI) are the standard of surgical treatment of patients with myocardial ischemia. However, up to 30% of patients experience complications of varying degrees within 12 months after the revascularization, or need for second intervention. Thus, it is necessary to search for additional approaches to the postoperative treatment of patients in order to improve the long-term results of revascularization treatment. Substances of natural origin with an anti-atherosclerotic effect have a good potential. These substances, as dietary supplements, can be taken by patients for a long time in conjunction with other prescribed medicines and treatments. Another valuable direction of investigations is the search for predictors of long-term cardiovascular complications after revascularization, which can be markers of inflammation and heteroplasmy levels of the patient's mitochondrial genome.

The purpose of this study is to determine whether the intake of dietary supplement Allicor at a daily dose of 300 mg affects the frequency of long-term postoperative cardiovascular complications and re-intervention in patients after revascularization operations on the coronary arteries. The second goal is assessing the relationship between the grade monocytes inflammatory response and the level of heteroplasmy of the mitochondrial genome of blood leukocytes with the frequency of cardiovascular complications and re-interventions.

Enrollment: 200 estimated patients

Sex: All

Ages: 40 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age >40 and <75 years
2. Patients with coronary arteries atherosclerosis for whom coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) is indicated
3. Patients passed a complex of instrumental and laboratory examinations before revascularization, including ECG, echocardiography, visualization of coronary vessels by X-ray contrast angiography, or CT, screening for atherosclerotic lesions of large arteries, including common carotid arteries, abdominal segment of the aorta, arteries of the lower extremities, biochemical analysis of blood included assessment of cholesterol, triglycerides, low density lipoproteins, high density lipoproteins and glucose levels.
4. The possibility of monitoring the patient for 12 months after revascularization, including phone contacts and visits to the clinic after 6 and 12 months.
5. Patient or legal authorized representative capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion criteria

1. Repeated revascularization surgery.
2. Critical and urgent cardiovascular conditions: tissue ischemia stage III-IV, stroke, acute coronary syndrome, myocardial infarction, chronic heart failure III and IV class NYHA (New York Heart Association).
3. Other critical and urgent conditions not associated with cardiovascular diseases, including the need for urgent interventions, chronic renal failure stages IV-V (creatinine clearance < 30 ml / min according to the Cockcroft-Gault Equation)
4. High degree of disability of the patient (4 or higher points on the modified Rankin scale).
5. History of systemic autoimmune diseases.
6. Significant weight loss (> 10% of body weight in the previous year) of unknown etiology.
7. Conditions that limit adherence to participation in the study (dementia, neuropsychiatric diseases, drug addiction, alcoholism, etc.).
8. Participation in other clinical studies (or use of investigational substances) within 3 months prior to study entry.
9. Patients with malignant tumors, including the postoperative period with chemotherapy and / or radiation therapy.
10. Carriers of HIV or viral hepatitis
11. Pregnancy or breast feeding
12. Refusal to participate in the study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

200 participants in 2 patient groups, including a placebo group

Allicor

Active Comparator group

Description:

Dietary Supplement: Allicor 150 mg capsule by mouth two times a day

Treatment:

Dietary Supplement: Allicor

Placebo

Placebo Comparator group

Description:

Placebo capsule manufactured to mimic Allicor 150 mg capsule by by mouth two times a day

Treatment:

Drug: Placebo